Pharmaceutical Technology

NOVEMBER 8, 2022

Additionally, Neurophth will oversee the clinical trials and marketing of gene therapy products developed leveraging the new AAV capsids of Cyagen. Both companies will assess the new AAV vectors’ functional effects in rodent and NHP models.

Gene Therapy 305

Gene Therapy Gene Development Genetics 305

pharmaphorum

JANUARY 19, 2022

The collaboration aims to “close the gap between single-cell RNA sequencing wet-lab services and single-cell data analysis solutions,” which will allow scientists to study the finest details that can be hard to access. Its mission is to introduce and accelerate the adoption of groundbreaking life science research tools to their markets.

RNA 72

RNA Research Life Science Bioinformatics 72

Roots Analysis

AUGUST 17, 2023

Genome sequencing has historically been classified into DNA sequencing and RNA sequencing. There are several RNA sequencing service providers coming in this market. Due to lack of in-house RNA sequencing facilities, many stakeholders are dependent on service provider, leads to rise demand of RNA sequencing services.

RNA 52

RNA DNA Genome Genomics 52

World of DTC Marketing

DECEMBER 29, 2020

Both the Pfizer and Moderna vaccines copied RNA sequence from the virus genome and found a way to manufacture it at scale with high-level processes and quality control. It’s estimated that the COVID 19 vaccine market could be worth almost $100 billion. The coronavirus vaccines, however, took less than a year.

Vaccine 307

Vaccine Vaccination Development Clinical Trials 307

BioTech 365

FEBRUARY 3, 2022

RNA-Dependent RNA Polymerase (RdRP or RNA Replicase) Inhibitor Drug Pipeline Market Research Report 2022 – ResearchAndMarkets.com RNA-Dependent RNA Polymerase (RdRP or RNA Replicase) Inhibitor Drug Pipeline Market Research Report 2022 – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The “RNA-Dependent RNA Polymerase (RdRP (..)

RNA 40

RNA Marketing Research Drugs 40

pharmaphorum

MAY 14, 2021

Biogen has made a further push into RNA-based drug discovery via a collaboration with Envisagenics, which applies artificial intelligence RNA sequencing data to discover new drug targets and therapeutics. It’s not the first partnership for Biogen in the RNA splicing area.

RNA 60

RNA Licensing Licensing Genetics 60

pharmaphorum

NOVEMBER 1, 2022

14th Annual RNA Therapeutics. Investigating the next generation of genetic medicine through RNA based therapies. RNA therapeutics is a rapidly expanding industry with increasingly growing potential for immunotherapy, personalised medicines, and treatment of genetic, infectious, and chronic diseases. Date: 8 – 9 February 2023.

RNA 52

RNA Genetics Gene Editing In-Vitro 52

BioTech 365

OCTOBER 21, 2021

Global RNA Analysis Market Research Report 2021 – ResearchAndMarkets.com Global RNA Analysis Market Research Report 2021 – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The “Global RNA Analysis Market 2021-2026” report has been added to ResearchAndMarkets.com’s offering.

RNA 40

RNA Marketing Research 40

BioTech 365

SEPTEMBER 13, 2021

Global RNA Analysis/Transcriptomics … Continue reading →

RNA 40

RNA Marketing 40

XTalks

NOVEMBER 15, 2024

XTALKS WEBINAR: Solutions for Vaccine Innovation and Gene Therapy: Unlocking the Power of RNA Live and On-Demand: Tuesday, December 17, 2024 , at 9am EST (3pm CET / EU-Central) Register for this free webinar to explore how next-generation RNA technologies can provide effective solutions for vaccine innovation and gene therapy.

Vaccine 105

Vaccine Vaccination Gene Therapy RNA 105

Pharmaceutical Technology

AUGUST 21, 2022

An RNA-dependent RNA polymerase (RdRp) inhibitor, ASC10 is an oral double prodrug. In March this year, the company filed applications seeking marketing authorisation for ritonavir in eight European countries, namely the Netherlands, Portugal, Spain, Denmark, Belgium, Poland, Sweden and Italy.

In-Vivo 162

In-Vivo RNA Clinical Development Drugs 162

Pharmaceutical Technology

MAY 2, 2023

4/5 Covid-19 messenger RNA (mRNA) vaccines. This led to a period of time when six mRNA vaccines, three from Pfizer/BioNTech and three from Moderna, were available in the US market. There are currently 32 vaccines in Phase III late-stage development across the seven major markets (7MM).

Vaccine 52

Vaccine Vaccination RNA Development 52

Pharmaceutical Technology

APRIL 3, 2023

In the dynamically growing market for cell and gene therapies, viral vectors are needed to deliver the genes of interest into cells. GlobalData, the parent company of Pharmaceutical Technology, outlines a rise in gene therapy trials in 2023, in line with the growing market Fáber describes.

Gene Therapy 246

Gene Therapy Gene DNA Reagent 246

BioTech 365

AUGUST 28, 2020

DUBLIN–(BUSINESS WIRE)–The “RNA-interference (RNAi) Market – Growth, Trends, and Forecast (2020 – 2025)” report has been added to ResearchAndMarkets.com’s offering. The RNA-interference (RNAi) market is expected to witness a CAGR of 10.12% during the forecast period.

RNA 40

RNA Marketing 40

BioTech 365

JANUARY 14, 2022

RNA Analysis / Transcriptomics Market Report 2021 – Global Trajectory & Analytics to 2026 – ResearchAndMarkets.com RNA Analysis / Transcriptomics Market Report 2021 – Global Trajectory & Analytics to 2026 – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The “RNA Analysis / Transcriptomics – Global (..)

RNA 40

RNA Marketing 40

pharmaphorum

JANUARY 6, 2022

Roivant is the latest pharma group to take a position in the emerging field of therapies targeted at RNA splicing, licensing exclusive rights to a drug developed by a unit of Japanese drugmaker Eisai. . The post Roivant joins RNA splicing push with Eisai deal appeared first on.

RNA 52

RNA Licensing Licensing Development 52

BioTech 365

FEBRUARY 3, 2022

Viral RNA Polymerase Inhibitor Drug Pipeline Market Research Report 2022: Therapeutics Scenario and Growth Prospects Across Viral RNA Polymerase Inhibitor Development – ResearchAndMarkets.com Viral RNA Polymerase Inhibitor Drug Pipeline Market Research Report 2022: Therapeutics Scenario and Growth Prospects Across Viral … Continue reading (..)

RNA 40

RNA Marketing Development Research 40

BioTech 365

JUNE 25, 2021

Africa DNA-RNA Sample Preparation Market Report 2021: Prospects, Trends Analysis, Market Size and Forecasts up to 2025 – ResearchAndMarkets.com Africa DNA-RNA Sample Preparation Market Report 2021: Prospects, Trends Analysis, Market Size and Forecasts up to 2025 – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The … Continue (..)

RNA 40

RNA DNA Marketing 40

BioPharma Reporter

SEPTEMBER 7, 2021

Moderna and the nonprofit Institute for Life Changing Medicines (ILCM) are collaborating to develop a new messenger RNA (mRNA) therapeutic (mRNA-3351) for Crigler-Najjar Syndrome Type 1 (CN-1), an ultra-rare disease.

Development 131

Development RNA Medicine Regulation 131

Pharma Mirror

FEBRUARY 2, 2022

Global contract development and manufacturing organisation (CDMO), Recipharm, has today announced the acquisition of GenIbet, a Portuguese CDMO, specialising in the manufacture of biological clinical trial material and novel modalities such as viral vectors, RNA and microbiome.

RNA 130

RNA Manufacturing Clinical Trials Clinical Trials 130

BioTech 365

SEPTEMBER 13, 2021

Growth Opportunities in RNA Therapeutics, Cancer Therapeutics & Diagnostics, and Lung Health Markets, 2021 Report – ResearchAndMarkets.com Growth Opportunities in RNA Therapeutics, Cancer Therapeutics & Diagnostics, and Lung Health Markets, 2021 Report – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The “Growth (..)

RNA 40

RNA Marketing 40

Pharmaceutical Technology

JULY 28, 2022

Cobitolimod, an agent being developed for patients with moderate to severely active UC, has both a novel MOA and a route of administration that is unique among marketed agents. Obefazimod is a micro-RNA-124 upregulator that ultimately inhibits the production of inflammatory mediators associated with UC.

Trials 246

Trials Marketing RNA Development 246

Pharmaceutical Technology

DECEMBER 11, 2022

The first subject was dosed in the trial, which is designed to evaluate the safety, tolerability and immunogenicity of a nucleoside-modified RNA-based combination vaccine approach. In November, the companies announced plans for a Phase I clinical trial of the combined vaccine candidate in healthy adult subjects.

Vaccine 289

Vaccine Vaccination Gene Therapy Gene 289

BioPharma Reporter

DECEMBER 6, 2021

Australiaâs Noxopharm has in-licensed novel RNA tech developed by Hudson Institute of Medical Research: focusing on RNA drug discovery and mRNA vaccine manufacture via Noxopharmâs subsidiary Pharmorage.

RNA 52

RNA Licensing Licensing Vaccine 52

BioTech 365

OCTOBER 7, 2021

Global DNA & RNA Banking Services (Storage Service, Quality Control Service) Market Trends, Analysis & Forecasts Report 2021-2028 – ResearchAndMarkets.com Global DNA & RNA Banking Services (Storage Service, Quality Control Service) Market Trends, Analysis & Forecasts Report 2021-2028 – ResearchAndMarkets.com … (..)

RNA 40

RNA DNA Marketing 40

BioTech 365

SEPTEMBER 13, 2021

United States RNA Analysis/Transcriptomics Market Research Report 2021 – Forecast to 2026 – Cumulative Impact of COVID-19 – ResearchAndMarkets.com United States RNA Analysis/Transcriptomics Market Research Report 2021 – Forecast to 2026 – Cumulative Impact of COVID-19 – ResearchAndMarkets.com DUBLIN–(BUSINESS (..)

RNA 40

RNA Marketing Research 40

Pharmaceutical Technology

OCTOBER 5, 2022

miRecule and Sanofi have entered a strategic partnership and exclusive licence agreement for the development and commercialisation of an antibody-RNA conjugate (ARC) to treat facioscapulohumeral muscular dystrophy (FSHD). The anti-DUX4 RNA therapy was discovered using the DREAmiR platform of miRecule.

Development 130

Development RNA Gene Therapy Sales 130

BioPharma Reporter

MARCH 9, 2023

Arranta Bio, a Recipharm company, is doubling capacity at its Massachusetts facility for process development services supporting RNA therapeutics.

RNA 52

RNA Development Regulation Marketing 52

BioTech 365

FEBRUARY 3, 2022

RNA Interference Drug Pipeline Market Research Report 2022: Insights About 20+ Companies and 20+ Pipeline Drugs in the Pipeline Landscape – ResearchAndMarkets.com RNA Interference Drug Pipeline Market Research Report 2022: Insights About 20+ Companies and 20+ Pipeline Drugs in the … Continue reading →

RNA 40

RNA Marketing Drugs Research 40

BioTech 365

MAY 7, 2021

Global RNA-based Therapeutics and Vaccines Market Trajectory & Analytics Report 2021: Market to Reach $499 Million by 2027 – Therapeutics to Grow at a CAGR of 68.1% Million – ResearchAndMarkets.com Global RNA-based Therapeutics and Vaccines Market Trajectory … Continue reading →

RNA 40

RNA Marketing Vaccine Vaccination 40

BioTech 365

DECEMBER 10, 2021

Global CRISPR Technology Market Research Report 2021: Focus on Design Tools, Plasmid and Vector, Cas9 and G-RNA, & Delivery System Products – ResearchAndMarkets.com Global CRISPR Technology Market Research Report 2021: Focus on Design Tools, Plasmid and Vector, Cas9 and G-RNA, … Continue reading →

RNA 40

RNA Production Marketing Research 40

Roots Analysis

NOVEMBER 6, 2023

RNA-based therapeutics have completely revolutionized the healthcare segment, greatly influencing the study and treatment of human diseases by conferring precise targeting ability to therapeutic modalities. The below figure presents the distribution of next generation RNA-based therapeutics and RNA-based vaccines, based on type of molecule.

RNA 40

RNA Vaccine Vaccination Clinical Trials 40

Roots Analysis

OCTOBER 30, 2023

In the past few years, Next Generation RNA therapeutics have emerged as one of the key therapeutic modalities in the modern healthcare industry. These RNA based therapeutics play a crucial role in protein production and regulation of gene functions.

RNA 40

RNA Vaccine Vaccination Development 40

BioPharma Reporter

JANUARY 23, 2023

Charles River Laboratories International, Inc and Rznomics Inc, a South Korea-based biopharmaceutical company specialized in the development of RNA-based gene therapeutics, have established a viral vector contract development and manufacturing organization (CDMO) partnership.

Gene 110

Gene Gene Therapy Development RNA 110

World of DTC Marketing

FEBRUARY 7, 2021

DTC marketers can tap into AI to help deliver relevant messages to certain audiences, but they shouldn’t let AI do all their thinking. Measuring RNA, DNA quickly. However, in DTC marketing, we should be careful about using AI in an era where too many patients feel like our healthcare system is dehumanizing them.

Doctors 164

Doctors Doctor Drugs Marketing 164

BioTech 365

MARCH 23, 2021

RSLV-132 by Resolve Therapeutics: A Novel RNase-Fc Fusion Protein Designed to Remove RNA – Global Emerging Insight and Market Forecast 2021-2030 – ResearchAndMarkets.com RSLV-132 by Resolve Therapeutics: A Novel RNase-Fc Fusion Protein Designed to Remove RNA – Global Emerging Insight … Continue reading →

RNA 40

RNA Protein Marketing 40

BioTech 365

SEPTEMBER 20, 2021

Global Gene Expression Market Size, Share & Trends Analysis 2021-2028 by Product (DNA Chip/Microarray, Kits & Reagents), Technique (Promoter Analysis, RNA Exp.) – ResearchAndMarkets.com Global Gene Expression Market Size, Share & Trends Analysis 2021-2028 by Product (DNA Chip/Microarray, Kits & … Continue reading → (..)

Gene Expression 40

Gene Expression Reagent DNA RNA 40